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Abstract
Background: The purpose of this study was to combine intraoperative gamma probe (GP) detection with preoperative
fluorine 18-fluoro-2-deoxy-glucose positron emission tomography (18F FDG-PET) imaging in order to improve detection
of tumor recurrence in colorectal cancer (CRC) patients.
Methods: Twenty-one patients (12 females, 9 males) with a mean age of 54 years (range 31–78) were enrolled. Patients
were suspected to have recurrent CRC by elevated CEA (n = 11), suspicious CT findings (n = 1), and clinically suspicious
findings (n = 9). Preoperative FDG-PET scan and intraoperative GP study were performed in all patients. Mean time
interval between preoperative FDG-PET scan and surgery was 16 days (range 1–41 days) in 19 patients. For
intraoperative GP studies, 19 patients were injected with a dose of 10–15 mCi 18F FDG at approximately 30 minutes
before the planned surgery time. In two patients, the intraoperative GP study was performed immediately after
preoperative FDG-PET scan.
Results: Preoperative FDG-PET and intraoperative GP detected 48 and 45 lesions, respectively. A total of 50 presumed
site of recurrent disease from 20 patients were resected. Thirty-seven of 50 presumed sites of recurrent disease were
histological-proven tumor positive and 13 of 50 presumed sites of recurrent disease were histological-proven tumor
negative. When correlated with final histopathology, the number of true positive lesions and false positive lesions by
preoperative FDG-PET and intraoperative GP were 31/9 and 35/8, respectively. Both preoperative FDG-PET and
intraoperative GP were true positive in 29 lesions. Intraoperative GP detected additional small lesions in the omentum
and pelvis which were not seen on preoperative FDG-PET scan. FDG-PET scan demonstrated additional liver metastases
which were not detected by intraoperative GP. Preoperative FDG-PET detected distant metastasis in the lung in one
patient.  The estimated radiation dose received by a surgeon during a single 18F FDG GP surgery was below the
occupational limit.
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Conclusion: The combined use of preoperative FDG-PET and intraoperative GP is potentially helpful to the surgeon as
a roadmap for accurately locating and determining the extent of tumor recurrence in patients with CRC. While
intraoperative GP appears to be more sensitive in detecting the extent of abdominal and pelvic recurrence, preoperative
FDG-PET appears to be more sensitive in detecting liver metastases. FDG-PET is also a valuable method in detecting
distant metastases.
Background
Colorectal cancer (CRC) remains the third leading cause
of new cancer cases and the third leading cause of cancer
deaths for both men and women in the United States [1].
Up to 50% of all CRC recurrences develop within two
years of the time of the initial surgery intervention [2-4].
In this regard, it is estimated that up to 50% of these local
recurrences may be suitable for attempted surgical extirpa-
tion [2-10]. Therefore, the accurate detection and localiza-
tion of all sites of tumor recurrence plays a critical role in
helping physicians to select the most appropriate thera-
pies to ultimately impact upon long-term patient out-
comes
The use of fluorine 18-fluoro-2-deoxy-glucose positron
emission tomography (18F FDG-PET) scan imaging as part
of the diagnostic work-up of patients with rising carci-
noembryonic antigen (CEA) is well-established [11-14].
FDG-PET has been shown to be superior to CT and MRI
for detecting local recurrences, as well as for detecting
metastatic disease to the liver and to distant sites [15-21].
In a recent meta-analysis, FDG-PET was determined to
have an overall sensitivity of 97% and overall specificity of
76% for detecting recurrent CRC [22]. Nevertheless, cur-
rent generation FDG-PET systems still have the limitation
of not detecting small-volume disease [23].
The concept of radioguided surgery employs the use of a
preoperative injection of a radiolabeled tumor imaging
agent and intraoperative detection of tumor via a hand-
held gamma probe (GP). Intraoperative GP studies with
radiolabeled monoclonal antibodies have previously
demonstrated that this method provides immediate intra-
operative staging, defines the extent of nodal involve-
ment, delineates resections margins, and localizes sites of
occult disease in patients with primary or recurrent CRC
[24-27]. Furthermore, 18F FDG detection using the intra-
operative GP has been shown to be feasible and correlates
well with preoperative FDG-PET imaging for detecting
sites of disease in CRC patients [28-30].
In the current study, we have set out to combine intraop-
erative GP detection with preoperative FDG-PET imaging
in order to attempt to improve intraoperative tumor
detection in patients with findings that are highly suspi-
cious for recurrent CRC.
Methods
Patients
This study protocol was approved by the Ohio State Uni-
versity (OSU) Comprehensive Cancer Center Scientific
Review Committee and by the Cancer Institutional
Review Board of the Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute and Comprehensive
Cancer Center of OSU.
The intraoperative GP study was performed in 21 patients
with presumed recurrent CRC, based on a positive preop-
erative FDG-PET scan. Likewise, 11 of these patients had
an elevated preoperative CEA level, one had a suspicious
CT scan, and nine had clinically suspicious findings. The
characteristics of the patients are summarized in Table 1.
FDG-PET imaging
FDG-PET imaging was performed as either combined
PET/CT studies on a Siemens Biograph 16 PET/CT camera
(CTI, Inc, Knoxville, TN) or as PET only studies on a HR
plus Siemens CTI PET camera (CTI, Inc, Knoxville, TN).
Combined PET/CT studies were performed in 18 patients
and PET only studies were performed in 3 patients. The
patients fasted approximately 6 hours prior to intravenous
injection of 370 to 555 MBq (10 to 15 mCi) 18F FDG.
Table 1: Patient Characteristics
Characteristics Patients
Mean age [range (year)] 54 (31–78)
Gender
Males 9
Females 12
Mean time interval from initial treatment to PET scan [range (months)] 42 (3–102)
Mean time interval from PET scan to Surgery/GP study [range (days)] 16(1–41)(19 patients)World Journal of Surgical Oncology 2007, 5:80 http://www.wjso.com/content/5/1/80
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Blood glucose levels were checked prior to the injection of
18F FDG. Studies were performed only when blood glu-
cose levels did not exceed 150 mg/dL. The imaging
sequence was started approximately 60 minutes following
the intravenous injection of 18F FDG. For the combined
PET/CT studies, first a scout view was obtained with 30
mAs and 130 kVp followed by a spiral CT scan with 130
mAs, 130 kVp, 5 mm scan width, and 12 mm feed per
rotation without any specific breath-holding instructions.
No IV or oral contrast was given to the patients for the CT
portion of the study. Imaging area was from the skull base
to the proximal femoral region. FDG-PET scanning was
performed immediately after acquisition of the CT images
without changing the patient position with 2 to 4 minutes
per bed acquisition time. FDG-PET images were corrected
for attenuation on the basis of the CT data, and iterative
reconstruction algorithms were used for reconstruction.
For the PET only studies, image acquisition time of 10
minutes per bed by using 40% transmission and 60%
emission protocol was used. FDG-PET images were cor-
rected for attenuation on the basis of the transmission
image data, and iterative reconstruction algorithms were
used for reconstruction. All FDG-PET images were evalu-
ated by two board-certified nuclear medicine physicians.
Quantification of the tumor metabolic activity was
obtained using the Standardized Uptake Value (SUV) nor-
malized to body weight.
Intraoperative GP studies
In 19 patients, the intraoperative GP studies were done a
time that was chronologically remote from the time of the
preoperative FDG-PET scan. In these 19 patients, the
mean time interval between the preoperative FDG-PET
scan and date of surgery for intraoperative GP was 16 days
(range 1 to 41 days). These 19 patients were intravenously
injected with 370 to 555 MBq (10 to 15 mCi) of 18F FDG
at approximately 30 minutes before the planned surgery
time. However, in two patients, the intraoperative GP
study was performed within 30 to 60 minutes after the
completion of the preoperative FDG-PET scan, and no
second dose of 18F FDG was administered.
The intraoperative GP device utilized was the Neoprobe
neo2000 unit (Neoprobe Corporation, Dublin, Ohio).
Intraoperatively, the GP device was used to systematically
obtain GP counts for all suspicious areas within the entire
operative field of interest. All examined areas with GP
counts determined to be greater than 3 standard devia-
tions above the background counts were considered
abnormal tissue. Lesion Count/Background Count (LC/
BC) ratios were calculated for lesions detected by the GP.
Statistical analyses
Mean ± standard deviation (SD) of maximum-pixel SUV
(SUVmax) and mean ± SD of LC/BC ratios of the lesions
were calculated. The significance of these values between
false positive and true positive lesions was compared by t-
test. A P-value of less than or equal to 0.05 was considered
statistically significant.
Calculation of estimated radiation dose to the surgeon 
during GP surgery
To estimate the 18F radiation dose to a surgeon, we meas-
ured radiation dose rates for several patients using a Vic-
toreen 450 P ionization chamber calibrated. The
measurements were taken at three distances, 0.152 m (6
inches), 0.305 m (12 inches) and 0.914 m (36 inches)
from patient's abdomen either on the right or left side.
The average elapsed time from the time of measurement
to the time of the 18F FDG injection was approximately
107 minutes. The measurements resulted in an average
dose rate of 163.7 μGy/hr at 0.152 m from the patient,
105.0 μGy/hr at 0.305 m, and 18.5 μGy/hr at 0.914 m.
Using the measured dose rates above, we calculated the
cumulative radiation dose to the surgeon at the three dis-
tances (0.152 m, 0.305 m and 0.914 m) for 1, 2, 3, 4, and
5 hour duration of operation. Since the surgery started
either approximately 30 minutes after or approximately 3
hours after the 18F FDG injection, we carried out calcula-
tion for both scenarios. Since the duration of operation
generally varied from one to five hours, we calculated a
cumulated radiation dose for five time intervals of 1, 2, 3,
4, and 5 hours.
In the calculation, we only took 18F physical decay (T1/2 =
110 m) into account and ignored the change in FDG bio-
distribution that may have occurred during the elapsed
time. We also made a theoretical assumption that the
patient had no urine voiding during this time period, so
that the estimate that was calculated would represent the
upper limit for radiation dose to the surgeon.
We first calculated the dose rate D(t) at different time t,
such as t = 30, 90, 150, 210, 270, and 330 minutes, using
the measured radiation dose rate D(107). In this equa-
tion, D(t) = D(107)·exp(0.693·(107-t)/110), 107 min-
utes is the time of measurement and 110 minutes is the
halftime of 18F. The cumulative dose for an one hour oper-
ation, defined as C(1 h), is then C(1 h) ≅ (D(tstart) +
D(tstart+1 h))/2, where tstart is the starting time of the oper-
ation and in this study is equal to either 30 minutes or 3
hours. Similarly, the cumulative dose for a two hour oper-
ation, defined as C(2 h), is then C(2 h) ≅ C (1 h) +
(D(tstart+1 h) + D(tstart+2 h))/2. This same method can be
applied to the cumulative dose for any operation lasting
more than 2 hours, defined as C(n). In any such situation,
C(n) ≅ C (n-1) + (D(tstart+n-1) + D(tstart+n))/2, with n
defining the duration of the operation.World Journal of Surgical Oncology 2007, 5:80 http://www.wjso.com/content/5/1/80
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Results
Preoperative CEA was elevated in 11 patients (mean 28.8
ng/mL, ranging from 5.2 to 181.1 ng/mL). In 8 patients,
preoperative CEA levels were within normal range. Preop-
erative CEA levels were not available in two patients. The
normal range for CEA in our clinical laboratory is 0 to 5.0
ng/mL (chemiluminescent immunoassay).
Preoperative FDG-PET and intraoperative GP detected 48
lesions (21 patients) and 45 lesions (17 patients), respec-
tively. Intraoperative GP was negative for GP activity in
four patients. A total of 50 presumed sites of recurrent dis-
ease from 20 patients were resected and sent for his-
topathologic evaluation. Six sites of presumed recurrent
disease identified by preoperative FDG-PET, but which
were not accessible or were negative by intraoperative GP,
were not resected. Likewise, two sites of presumed recur-
rent disease identified in the external inguinal region by
both preoperative FDG-PET and intraoperative GP were
not resected. Thirty-seven of the 50 tissues specimens
(from a total of 17 patients) were histological-proven
tumor positive and 13 specimens (from a total of 8
patients) were histological-proven tumor negative (Table
2). When correlated with final pathology, the number of
the true positive lesions by preoperative FDG-PET and
intraoperative GP were 31 and 35, respectively (Table 3).
The number of false positive by preoperative FDG-PET
and intraoperative GP were nine and eight, respectively
(Table 3). Both preoperative FDG-PET and intraoperative
GP accurately detected 29 of 37 pathologically proven
sites of recurrent tumor. The location of the lesions by pre-
operative FDG-PET and intraoperative GP are shown on
body diagrams in Figure 1. Intraoperative GP detected six
additional tumor foci that were not identified on preoper-
ative FDG-PET. These tumor foci were all less than one
centimeter in size and were generally located within the
omentum and deep pelvis. Preoperative FDG-PET scan
demonstrated two additional liver metastases in two
patients which were not detected by intraoperative GP
(Figure 2).
In three patients (patient number 4, 15, and 18), his-
topathologic evaluation failed to demonstrate recurrent
tumor within any of the tissues resected. In patient
number 4, the preoperative CEA level was 1.6 ng/mL and
the preoperative FDG-PET scan demonstrated a hypermet-
abolic focus in the pelvis. However, histopathologic eval-
uation of the resected tissues failed to demonstrate
recurrent tumor. This patient's multiple postoperative
CEA levels during 16 months of follow-up have remained
within normal limits. In patient number 15, the preoper-
ative FDG-PET scan demonstrated multiple hypermeta-
bolic foci within the liver, retroperitoneum, and pelvis.
The preoperative CEA level was only 0.5 ng/mL. Intraop-
erative GP was positive for the liver, pelvis, and portal
region. In this patient, histopathologic evaluation of all
resected tissues failed to demonstrate recurrent tumor.
This patient's follow-up CEA level at 2 months remained
within normal limits. A subsequent follow-up FDG-PET
scan in 6 months demonstrated a decrease in metabolic
activity in these lesions and additional histopathology fol-
lowing subsequent surgical resection of lesions within the
liver and lymph nodes was also negative. In patient
number 18, the preoperative CEA level was 9.5 ng/mL and
the preoperative FDG-PET scan demonstrated suspicious
lesions in the liver and anal region. However, intraopera-
tive GP was negative and tissue sampling from the liver
was negative for tumor recurrence. In this case, the CEA
PET/CT fusion image on transaxial section demonstrates a  hypermetabolic lesion (SUVmax : 8.2, Patient number 14) in  the segment 6 of the liver (arrow) which could not be  detected by GP Figure 2
PET/CT fusion image on transaxial section demonstrates a 
hypermetabolic lesion (SUVmax : 8.2, Patient number 14) in 
the segment 6 of the liver (arrow) which could not be 
detected by GP. Final pathology was consistent with CRC 
metastasis.
Location of the lesions detected by PET and GP Figure 1
Location of the lesions detected by PET and GP.
PET GP
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level at a time two months follow-up was noted to have
further increased.
In patient number 11, the preoperative CEA level was 9.2
ng/mL and the preoperative FDG-PET scan demonstrated
only a hypermetabolic right lung lesion. This was not
accessible with the intraoperative GP and was not
resected. Likewise, intraoperative GP was also negative
within the abdomen and pelvis. Therefore, no specimens
were sent on patient number 11. A follow-up FDG-PET
scan demonstrated progression of the right lung lesion
and a further increase in the CEA level. This lesion was
subsequently surgically resected and histopathology con-
firmed that this was a CRC metastasis.
In three patients in which the histopathology of the tumor
recurrence was specifically classified as mucinous adeno-
caricoma, both preoperative FDG-PET and intraoperative
Table 2: Location and pathology findings of the lesions detected by PET and GP
Pt No PET [Location(No)] GP [Location(No)] Pathology Follow-up
1 Liver (3) Liver (3) +++ PET&GP
Portal (3) Portal (3) +++ PET&GP
Rectum Rectum + PET&GP
2 Liver Liver + PET&GP
3 Rectum Rectum + PET&GP
4 Pelvis - - PET - CEA
5 Rectum Rectum + PET&GP
Pelvis - - PET
6 Rectum Rectum + PET&GP
7 Liver - No specimen sent
RLQ - - PET
Pelvis Pelvis (3) + PET; +++ GP
8 RLQ (2) - No specimen sent
Pelvis Pelvis + PET&GP
- Liver (2) -- GP
9 Pelvis Pelvis + PET&GP TV adenoma in 
colon
10 Small bowel Small bowel + PET&GP
Pelvis Pelvis (3) + PET; +++ GP
- Omentum + GP
11 Lung Not accessible No specimen sent + PET, + CEA, + Path.
12 Pelvis Pelvis + PET&GP
13 Liver (3) Liver (2) ++- PET; +- GP
- Small bowel - GP
14 Liver - + PET
15 Liver Liver - PET&GP - CEA, - PET, - Path
Retoperitoneum - - PET
Pelvis Pelvis - PET&GP
RLQ - No specimen sent
-P o r t a l -  G P
16 Pelvis Pelvis + PET&GP
17 Pelvis Pelvis + PET&GP
18 Liver - - PET + CEA
Anus - No specimen sent
19 Peritoneum Peritoneum + PET&GP
- Omentum + GP
20 Rectum Rectum - PET&GP
Pelvis (2) Pelvis (2) ++ PET&GP
Liver Liver + PET&GP
21 Abdominal wall Abdominal wall + PET&GP
Pelvis (2) Pelvis (2) ++ PET&GP
Mesenterium Mesenterium + PET&GP
Peritoneum Peritoneum + PET&GP
Inguinal (2) Inguinal (2) No specimen sent
Pt No (Patient number); RLQ (Right lower quadrant); TV (Tubulovillous); Path (Pathology); - (Negative); + (Positive).World Journal of Surgical Oncology 2007, 5:80 http://www.wjso.com/content/5/1/80
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GP were able to detect all sites of tumor recurrence. In two
of these patients, the SUVmax and GP counts were mark-
edly elevated and in one patient there was only a mild
increase in the SUVmax and GP counts.
The mean LC/BC ratios in true positive and false positive
lesions by intraoperative GP were 1.68 ± 0.57 and 2.36 ±
2.50, respectively (P = 0.50071). The mean SUVmax in true
positive and false positive lesions were 8.27 ± 4.76 and
3.65 ± 1.22, respectively (P = 0.00021).
The estimated radiation doses to the surgeon during GP
surgery are shown in Tables 4 and 5. A maximum radia-
tion dose of approximately 606 μGy would occur to a sur-
geon who maintains a distance of 0.152 m away from the
patient during a five hour operation that started 30 min-
utes after 18F FDG administration (Table 4), while a min-
imum radiation dose of less than 10 μGy would occur to
a surgeon who maintains a distance of 0.914 m away from
the patient during an one hour operation that started
three hours after 18F FDG administration (Table 5). All
other proposed operation scenarios would fall some-
where between these two extremes.
Discussion
The accurate assessment of the location and extent of all
sites of intraabdominal and intrapelvic tumor recurrence,
as well as of all sites of distant metastatic disease, plays a
critical role in optimizing therapeutic strategies for delay-
ing the development of further disease in CRC patients.
Utilizing such an approach can lead to improvement in
long-term outcome for CRC patients faced with this far
too common sequela.
Numerous studies have demonstrated that FDG-PET has
high sensitivity and high specificity for the detection of
tumor recurrence in CRC patients with rising CEA levels in
which there are no identifiable sites of tumor recurrence
by standard anatomical imaging methods [11-14]. Partic-
ularly, combined PET/CT is superior to CT and MRI for
the detection of CRC local recurrences, as well as meta-
static disease to the liver and other distant sites [15-21].
However, the current FDG-PET scanning systems have
several limitations. One of the most important limitations
of FDG-PET scanning is its low sensitivity in detecting
small sized lesions (23). FDG-PET has limited ability to
detect lesions measuring less than 5 to 10 mm in size. A
second limitation of FDG-PET imaging is the limited abil-
ity to assess local tumor invasion into the surrounding tis-
sues. Strictly speaking, PET only imaging cannot identify
local tumor invasion into the surrounding tissues second-
ary to the absence of anatomical correlation, as can be
provided by combined PET/CT imaging. Nevertheless,
while combined PET/CT imaging may be helpful in this
regard if deeper tumor invasion is present, it will not be
able to assess more limited tumor invasion. An additional
limitation of FDG-PET imaging is its limited sensitivity for
the detection of tumors that display a low metabolic activ-
ity [17]. Finally, 18F FDG is limited by the fact that it is not
cancer-specific, and resultant physiological uptake into
benign tissue processes, such as infection and inflamma-
tion, can result in the identification of areas of increased
uptake of 18F FDG.
Over the last 20 years, intraoperative GP detection of
tumor has been extensively studied in CRC patients by
Martin and his colleagues at The Ohio State University
[24-29,31-42]. For most of these studies, a mechanism of
Table 4: Cumulative radiation dose in GP surgeries starting approximately 30 minutes after 18F FDG administration
Cumulated Dose (μGy) @ 0.152 m Cumulated Dose (μGy) @ 0.305 m Cumulated Dose (μGy) @ 0.914 m
1 hr 224.5 144.0 25.4
2 hr 378.4 242.7 42.8
3 hr 483.8 310.3 54.7
4 hr 556.0 356.6 62.8
5 hr 605.5 388.4 68.4
Table 3: Number of the lesions detected by PET and GP
TP FP NE
PET 31 9 8
GP 35 8 2
Both PET and GP Positive 29 4 2
Only PET Positive but GP Negative 25 6
Only GP Positive but PET Negative 64 0
NE: Not evaluated by pathologyWorld Journal of Surgical Oncology 2007, 5:80 http://www.wjso.com/content/5/1/80
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cancer-specific detection was designed in which mono-
clonal antibodies against TAG-72 tumor-associated glyco-
protein that were coupled with iodine-125. This
technology has been trademarked as Radioimmunogu-
ided Surgery (RIGS). RIGS has been shown to be very use-
ful in determining the surgical resection margins, in
defining the extent of nodal involvement, and as a
method of immediate intraoperative staging [24,26,27].
All these aspects of RIGS ultimately lead to a reduction in
the risk for future recurrences. The use of RIGS was also
been shown to impact upon the intraoperative strategy,
thus altering the type of surgical procedure performed in
some cases and avoiding major extirpation procedures in
other cases in which chemotherapy and radiotherapy were
decided to be given [26,27]. Finally, RIGS has been instru-
mental in defining sites of occult disease [24-27], in which
the RIGS positive tissues have been shown to contain
micrometastatic disease by immunohistochemistry
despite the fact that these same tissues were negative on
routine hematoxylin and eosin (H&E) staining (33).
In more recent years, several groups have utilized 18F FDG
as a tumor targeting agent for intraoperative GP studies. In
patients with CRC, intraoperative GP results have been
shown to correlate well with preoperative FDG-PET
results [28-30]. The combination of these two techniques
has helped to improve the surgeon's ability to obtain a
complete resection of primary or residual tumors [28].
The authors of these studies have emphasized the point
that intraoperative GP removal of all 18F FDG positive tis-
sue ensures for more complete removal of the tumor bur-
den as compared to the surgeons' more traditional hands-
on approach of assessing and resecting presumed sites of
tumor. In this regard, Essner et al used 18F FDG and the
intraoperative GP to assist in differentiating normal tissue
from tumor-bearing tissue in patients with metastatic
CRC and melanoma [30].
In our current study, intraoperative GP tumor localization
correlated well with the findings on preoperative FDG-
PET imaging. Over three-fourths (29 of 37) of the his-
topathologic confirmed sites of tumor recurrence were
detected by both preoperative FDG-PET imaging and
intraoperative GP. The intraoperative GP detected more
sites of recurrent tumor within the abdomen and pelvis.
These tumors were less than one centimeter in size and
were located within the omentum and deep pelvis. In this
particular regard, the main advantage of the intraoperative
GP over that of preoperative FDG-PET imaging is the abil-
ity to have the intraoperative GP in close proximity to the
suspected site of recurrent disease at the time of surgery.
This same contention has also been put forth by Barber et
al, in which they previously showed that a sodium iodide
based scintillation probe was more sensitive in detecting
small, deep tumors than was a gamma camera over a wide
range of conditions, provided that the probe was placed
within one centimeter of the tumor (43).
In our current study, preoperative FDG-PET scan accu-
rately demonstrated liver metastases in two patients with
histopathology proven metastasis which could not be
detected by the intraoperative GP. It is apparent that
tumors located more deeply within the liver may not be
optimally detected by intraoperative GP, given the fact
that the physiologic activity of 18F FDG within the liver in
areas overlying and surrounding the presumed tumor may
interfere with its accurate intraoperative GP detection.
Although physiologic activity of 18F FDG within the liver
can also be problematic in FDG-PET imaging, the process
of separating the overlying and underlying activity into
sequential tomographic planes allows FDG-PET imaging
to increase image contrast and improve lesion detection
and localization within deeper tissue planes.
In our current study, preoperative FDG-PET demonstrated
a lung metastasis in one patient. This pulmonary lesion
was not accessible with the intraoperative GP. Neverthe-
less, previous studies have demonstrated that preopera-
tive FDG-PET can be a valuable imaging tool to detect
distant metastases and to help differentiate isolated resect-
able recurrence from that of disseminated metastatic dis-
ease and thus help select appropriate CRC patients who
would benefit from attempted surgery resection [16,21].
A recognizable limitation to both FDG-PET imaging and
intraoperative GP detection is the physiologic 18F FDG
activity which can be demonstrated within nonmalignant
tissues. This is especially evident in the scenario in which
increased 18F FDG activity is seen in associated with infec-
tious and/or inflammatory changes within nontumor-
Table 5: Cumulative radiation dose in GP surgeries starting approximately 3 hours after 18F FDG administration
Cumulated Dose (μGy) @ 0.152 m Cumulated Dose (μGy) @ 0.305 m Cumulated Dose (μGy) @ 0.914 m
1 hr 87.3 56.0 9.9
2 hr 147.0 94.3 16.6
3 hr 188.0 120.6 21.2
4 hr 216.1 138.6 24.4
5 hr 235.3 150.9 26.6World Journal of Surgical Oncology 2007, 5:80 http://www.wjso.com/content/5/1/80
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bearing tissues. Such a scenario creates false positive
results with both preoperative FDG-PET imaging and
intraoperative GP detection techniques [44]. Likewise, it is
well established that mucinous tumors are more difficult
to identify with FDG-PET imaging, likely secondary to a
lower metabolic activity of such tumors. It has been previ-
ously reported that the sensitivity of FDG-PET imaging for
the detection of mucinous carcinoma is significantly
lower than that of nonmucinous carcinoma (58% and
92%, respectively) [17]. This would also be the expecta-
tion for intraoperative GP detection of 18F FDG. Neverthe-
less, in our current study, the sites of tumor recurrence
were accurately detected by both FDG-PET imaging and
intraoperative GP detection in those three patients whose
CRC recurrence represented mucinous adenocarcinoma.
Although previous studies suggest that both preoperative
FDG-PET imaging and intraoperative GP detection may
not as effectively identify mucinous tumors, the surgeon's
ability to position the intraoperative GP in close proxim-
ity to sites of suspected tumor recurrence may ultimately
make intraoperative GP detection more efficient for the
detection of mucinous tumors as compared to preopera-
tive FDG-PET imaging.
The estimated radiation dose received by a surgeon during
a single 18F FDG GP surgery was much lower than the
occupational limit of 50 mGy/yr (50,000 μGy/yr) and
even below the limit for the general public of 1 mGy/yr
(1,000 μGy/yr), as determined and mandated by Federal
regulations. With no special shielding from radiation, the
radiation dose should not cause health hazard to any
given surgeons during a single 18F FDG GP surgery. How-
ever, for surgeons who perform multiple 18F FDG GP
operations, the cumulative radiation dose will be the sum
of each single radiation dose. Depending on how many
18F FDG GP operations are performed by a given surgeon
during a finite period of time, the cumulative radiation
dose to the surgeon may significantly increase and may
even exceed regulatory limits. In order to comply with
Federal regulations, the number of 18F FDG GP operations
performed by a given surgeon during a finite period of
time will need to be monitored and limited in such a fash-
ion as to keep the cumulative radiation dose to the sur-
geon to within the occupational limit of 50 mGy/yr
(50,000 μGy/yr).
Conclusion
The combined use of preoperative FDG-PET imaging and
intraoperative GP detection is potentially helpful to the
surgeon as a roadmap for accurately locating and deter-
mining the extent of tumor recurrence in patients with
CRC. While the intraoperative GP appears to be more sen-
sitive in detecting the extent of abdominal and pelvic
recurrence, preoperative FDG-PET imaging appears to be
more sensitive in the detecting liver metastases. FDG-PET
imaging also detects unexpected distant metastases.
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